Hutch News
Results per Page:
New Science Spotlight Articles
Every month, Fred Hutch postdoc writer/editors summarize two papers from each of our scientific divisions to stimulate collaborations across campus
January 17, 2022
Potential strategies for mitigating CD19 CAR T-cell associated toxicities
From the Gauthier Group, Clinical Research Division
New Scientific Publications
Each week, Fred Hutch librarians search PubMed and Web of Science to discover new papers published by Fred Hutch authors
Week of January 16, 2022
Hopes and predictions for 2022
Hutch researchers look ahead to an increase in cancer screening, improved vaccines and greater trust in science
Vaccination after CAR-T-cell therapy
From the Hill group, Vaccine and Infectious Disease Division and the UW/Fred Hutch Cancer Consortium
Fred Hutch at ASH: Latest findings in CAR T-cell therapy, microbiome effects on transplantation, post-transplant COVID-19 — and single-cell genomics for residual disease
The 63rd American Society of Hematology Annual Meeting and Exposition will take place virtually and in person Dec. 11–14 in Atlanta, Georgia
Fred Hutch mourns sudden loss of Dr. Martin ‘Mac’ Cheever
A long career devoted to bringing immunotherapies from bench to bedside
Investment in business development pays dividends for research, patients
Fred Hutch tech transfer specialists help scientists navigate path to bringing innovations to patients
Dr. Mazyar Shadman receives the 2021 Ali Al-Johani Award
Oncologist lauded for his compassion and care for bone marrow transplant patients
Keep your enemies closer: targeting membrane-proximal domains for improved immunotherapy
From the Walter Lab, Clinical Research Division
Remodeling the tumor microenvironment for improved CAR T-cell therapy
From the Riddell and Srivastava Labs, Clinical Research Division
What's next for T-cell therapies: Q&A with Dr. Stanley Riddell
After approval of latest cellular therapy for non-Hodgkin lymphoma, the immunologist looks ahead
Fred Hutch statement regarding the FDA approval of CD19 immunotherapy, lisocabtagene maraleucel
The newly-approved CAR T-cell therapy was developed in part by Fred Hutch physician-scientists
Tip Sheet: Looking ahead to 2021, COVID-19 vaccines, improving health outcomes — and more
Summaries of recent Fred Hutch research findings and other news
Scientists predict progress against COVID-19, cancer in 2021
After a challenging and deadly 2020, some hopeful predictions for the new year
What’s new in breast cancer research? SABCS20 goes virtual
Hutch scientists share findings on treatment, imaging, CAR T therapy, COVID-19’s impact on cancer patients and more
Advances in blood disorders research continue despite COVID-19
Expanding use of CAR T-cell therapies, gene editing lead to insights at virtual annual meeting of the American Society of Hematology
Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots — and more
The 62nd American Society of Hematology Annual Meeting and Exposition to be held virtually Dec. 5-8, 2020
If at first you don’t succeed: Testing outcomes of second CAR T-cell infusions
From the Turtle group and collaborators, Clinical Research Division
Fred Hutch research a GeekWire Award finalist for Health Innovation of the Year
Other finalists include Fred Hutch spinoffs Adaptive Biotechnologies and Blaze Bioscience
Does CAR T-cell therapy leave patients vulnerable to infection?
$3.3M Cancer Moonshot grant to study how immunotherapy impacts patients’ ability to fight off bugs